AU2020300792B2 - Methylthioninium for use in the treatment of synaptopathies - Google Patents

Methylthioninium for use in the treatment of synaptopathies

Info

Publication number
AU2020300792B2
AU2020300792B2 AU2020300792A AU2020300792A AU2020300792B2 AU 2020300792 B2 AU2020300792 B2 AU 2020300792B2 AU 2020300792 A AU2020300792 A AU 2020300792A AU 2020300792 A AU2020300792 A AU 2020300792A AU 2020300792 B2 AU2020300792 B2 AU 2020300792B2
Authority
AU
Australia
Prior art keywords
lmtm
acid
compound
treatment
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020300792A
Other languages
English (en)
Other versions
AU2020300792A1 (en
Inventor
Charles Robert Harrington
Gernot Riedel
Claude Michel Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taurx Therapeutics Management Ltd
Original Assignee
Taurx Therapeutics Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taurx Therapeutics Management Ltd filed Critical Taurx Therapeutics Management Ltd
Publication of AU2020300792A1 publication Critical patent/AU2020300792A1/en
Assigned to TauRx Therapeutics Management Ltd reassignment TauRx Therapeutics Management Ltd Request for Assignment Assignors: WISTA LABORATORIES LTD.
Application granted granted Critical
Publication of AU2020300792B2 publication Critical patent/AU2020300792B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020300792A 2019-07-02 2020-06-29 Methylthioninium for use in the treatment of synaptopathies Active AU2020300792B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909506.6 2019-07-02
GBGB1909506.6A GB201909506D0 (en) 2019-07-02 2019-07-02 Synaptopathies
PCT/EP2020/068306 WO2021001326A1 (en) 2019-07-02 2020-06-29 Methylthioninium for use in the treatment of synaptopathies

Publications (2)

Publication Number Publication Date
AU2020300792A1 AU2020300792A1 (en) 2022-02-24
AU2020300792B2 true AU2020300792B2 (en) 2026-03-19

Family

ID=67540130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020300792A Active AU2020300792B2 (en) 2019-07-02 2020-06-29 Methylthioninium for use in the treatment of synaptopathies

Country Status (12)

Country Link
US (1) US20220370470A1 (enExample)
EP (1) EP3993805A1 (enExample)
JP (1) JP7610537B2 (enExample)
KR (1) KR20220029711A (enExample)
CN (1) CN114080224A (enExample)
AU (1) AU2020300792B2 (enExample)
BR (1) BR112021025383A2 (enExample)
CA (1) CA3143787A1 (enExample)
GB (1) GB201909506D0 (enExample)
IL (1) IL289371A (enExample)
MX (1) MX2021015288A (enExample)
WO (1) WO2021001326A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148145A (en) 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
WO2021211640A1 (en) * 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP6756661B2 (ja) 2017-04-28 2020-09-16 日立オートモティブシステムズ株式会社 車両電子制御装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATJA HOCHGR?FE;ASTRID SYDOW;DORTHE MATENIA;DANIELA CADINU;STEFANIE K?NEN;OLGA PETROVA;MARCUS PICKHARDT;PETRA GOLL;FABIO MORELLINI: "Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau", ACTA NEUROPATHOLOGICA COMMUNICATIONS, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 10 May 2015 (2015-05-10), London, UK, pages 25, XP021222090, ISSN: 2051-5960, DOI: 10.1186/s40478-015-0204-4 *
Riedel G, et al. Curr Alzheimer Res. 2020;17(3):285-296. doi: 10.2174/1567205017666200224120926. PMID: 32091331; PMCID: PMC7403648. *

Also Published As

Publication number Publication date
JP7610537B2 (ja) 2025-01-08
KR20220029711A (ko) 2022-03-08
CN114080224A (zh) 2022-02-22
US20220370470A1 (en) 2022-11-24
MX2021015288A (es) 2022-01-18
CA3143787A1 (en) 2021-01-07
AU2020300792A1 (en) 2022-02-24
JP2022538286A (ja) 2022-09-01
GB201909506D0 (en) 2019-08-14
BR112021025383A2 (pt) 2022-02-01
IL289371A (en) 2022-02-01
WO2021001326A1 (en) 2021-01-07
EP3993805A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
AU2020300792B2 (en) Methylthioninium for use in the treatment of synaptopathies
US20230165877A1 (en) Administration and dosage of diaminophenothiazines
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
JP4638148B2 (ja) 神経変性疾患および脳の癌の処置
EP4364801B1 (en) Optimised dosage of diaminophenothiazines in populations
JP7757446B2 (ja) リソソーム蓄積障害に関する医薬組成物及び使用
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
AU2020298737B2 (en) Methylthioninium as enhancers of the cognitive function
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
SG188144A1 (en) Alpha 7 nicotinic agonists and antipsychotics
US20100099762A1 (en) Combination therapy
CA2807510A1 (en) Inhibitors of erk for developmental disorders of neuronal connectivity
AU2015343060A1 (en) Methods of treating Huntington's Disease using cysteamine compositions
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
RU2835868C2 (ru) Метилтиониний, предназначенный для лечения синаптопатий
Majlath et al. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
EP4541372A1 (en) Drug therapy for obsessive-compulsive disorder targeting dopamine d1 signal in striatal striosomes
HK40109096B (en) Optimised dosage of diaminophenothiazines in populations
JP2025518248A (ja) メチルチオニニウム（ｍｔ）含有化合物を利用した神経変性障害の処置
JP2018528953A (ja) リソソーム障害及び中枢神経系の変性障害の治療及び予防のための（３ｒ，４ｒ，５ｓ）−５−（ジフルオロメチル）ピペリジン−３，４−ジオールを含むレジメン
HK40106579B (en) Administration and dosage of diaminophenothiazines
JP2023064002A (ja) Ｍａｒｋ４阻害活性を有する新規ペプチド

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAURX THERAPEUTICS MANAGEMENT LTD

Free format text: FORMER APPLICANT(S): WISTA LABORATORIES LTD.